Unicycive shares surge 10.19% intraday after announcing Q3 2025 financial results and business update.

Unicycive Therapeutics, Inc. (UNCY) rose 10.19% intraday following the release of its third-quarter 2025 financial results and business update. The announcement, which occurred during market hours, highlighted progress in regulatory engagements, including plans to resubmit an NDA for oxylanthanum carbonate before year-end, and reinforced the company’s pipeline advancements. The positive reception of these updates, coupled with renewed investor confidence in its hyperphosphatemia treatment development, drove the sharp intraday rally. Other recent events, such as a U.S. patent grant and upcoming data presentations, provided additional context but were less immediately impactful than the Q3 earnings report.